As we are getting to the end of this year’s Advanced Therapies UK 2025, we come back with still significant concerns on what’s ahead of us in this field, especially in the funding of early preclinical stage biotechs. The current turmoil created by the US new administration is having very damaging effect on our business and will likely continue to negatively impact upcoming activities and developments for many months. On the positive side, our CEO Rapha?l G. Ognar, MSc MBA highlighted our current developments across hematologic and solid tumors and initiated many European contacts for us to leverage and consider. We always wanted to set ground in Europe and we clearly believe more and more in such opportunity.
NKILT Therapeutics, Inc.
生物技术研究
Houston，Texas 2,135 位关注者
Engineering the future of targeting Natural Killer off-the-shelf cell therapy against cancer.
关于我们
NKILT Therapeutics is a preclinical cell therapy biotech developing a novel off-the-shelf approach with a proprietary and first-in-class engineered CIR?NK cells that targets HLA-G, expressed in over 50% of hematologic and solid tumors. Our unique technology enhances NK cell potency and functional persistence to safely increase depth and duration of response, while improving scalability speed and patient access. Our approach is based on the novel Chimeric ILT-Receptor (CIR?), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial engineered CIR?NK cells will be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor’s defense mechanisms. As we are building our path to IND, the first indication will be Acute Myeloid Leukemia (AML) as a pre-clinical/clinical proof of concept, while our core focus is to expand to a large array of HLA-G+ tumors, especially solid tumors such as Colorectal Cancer (CRC), Bladder Cancer, Ovarian Cancer, Renal Cell Carcinoma (RCC), or Endometrial Cancer.
- 网站
-
https://www.nkilt.com
NKILT Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Houston，Texas
- 类型
- 私人持股
- 创立
- 2021
- 领域
- Cell Therapy、NK Cells、Immuno-Oncology、Biotechnology、Cancer Research、Oncology、Hematology、Leukemia、Solid Tumors、HLA-G和Immune Cell Engineering
地点
-
主要
获取路线
2170 Reed Rd
Suite 160
US，Texas，Houston，77051
NKILT Therapeutics, Inc.员工
-
Carlos Martin
Chief Commercial Officer | Oncology, Rare Diseases, Nuclear Medicine | General Manager, Business Leader within Large and MidSize Organizations
-
Chris Conley
I ?? Biotech - Startup Advisor - Company Builder - Consultant
-
Joseph Senesac
-
Rapha?l G. Ognar, MSc MBA
Oncology/Hematology Biotech and Pharma C-Suite Executive leader, specialized in Cell Therapy and Immuno-Oncology.
动态
-
Live from Advanced Therapies UK in London with a very nice and dynamic panel discussion on modalities in cell therapies, led by our CEO Rapha?l G. Ognar, MSc MBA to kick off the Cell therapy Track. A lot of exchanges and aligned statements on how we need to pursue the development of autologous, allogeneic and in vivo cell therapies, to ensure better fit-for-purpose options for patients.
-
-
Advanced Therapies UK is on, and our CEO Rapha?l G. Ognar, MSc MBA is already on stage for some great debate on modalities in cell therapy. Today he will be chairing a session at 11am and then will present the latest of our developments at 4:30pm. We hope to see you there!
Oncology/Hematology Biotech and Pharma C-Suite Executive leader, specialized in Cell Therapy and Immuno-Oncology.
Time for some EU networking and exciting discussions at Advanced Therapies UK in London. As a kick off for me I am thrilled to be chairing a “classic” panel discussion about autologous vs. allogeneic, with distinguished panelists surrounding me: Eleuterio Lombardo , Ibon Garitaonandia, PhD, MBA , Johannes de Munter , Stefanos Theoharis & Giuliana Vallanti . I am always very proud to showcase our work at NKILT Therapeutics, Inc. And discuss with peers on how we can bring off-the-shelf cell therapies to more patients. Come and talk with us !
-
-
Our leadership continues to showcase the progress and new developments of our off-the-shelf cell therapy targeting hematologic and solid tumors. Our CEO Rapha?l G. Ognar, MSc MBA will be presenting at the upcoming Advanced Therapies Congress in London, March 18-19. This is another opportunity to learn more about the unique capabilities of our technology and engage with partners and investors. We hope to see you there!
Bringing together global life science leaders across multiple events in Europe and the USA
?? Final Early Bird Reminder! ?? Don't miss your chance to join the Advanced Therapies Congress UK in London on March 18–19, 2025, at Excel London. Event Highlights: 2,500+ global executives 300+ speakers 100+ biotech start-ups 100+ exhibitors 2 days of immersive content Featured Speakers: Eric David of Gene Therapy at BridgeBio Gene Therapy Jordan Schecter, MD, VP & Multiple Myeloma DAS Leader at Johnson & Johnson Oluwayemisi Corinaldi, Senior Director, Head of EU/International Regulatory Affairs at Spark Therapeutics, Inc. Nick France, MD (MBChB) MRCPCH, VP, Head of Genomic Medicine Development Unit at Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease Francis Pang, SVP, Global Market Access and Geographic Expansion at Orchard Therapeutics - U.S. Paolo Morgese, VP Public Affairs, Europe at Alliance for Regenerative Medicine Joshi Venugopal General Manager and Head of Europe at Novartis Gene Therapies Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU at AstraZeneca Olga de la Rosa Morales, Madrid Cell Therapy Technology Head at Takeda Rapha?l G. Ognar, MSc MBA, President & CEO, Co-founder at NKILT Therapeutics, Inc. James Levine, President, Foundation Ipsen at Ipsen Volker Huppert, Chief Operating Officer at Glycostem Therapeutics Dilip Patel, SVP, Pricing & Market Access Strategy at Autolus Therapeutics Dame Molly Stevens DBE, John Black Professor of Bionanoscience at University of Oxford Ben Doak, Head of Innovative Treatments at NHS England Secure your spot before the early bird pricing ends this Friday! ?? Register Now: https://lnkd.in/e96AR76g #AdvancedTherapies #GeneTherapy #Biotech #RegenerativeMedicine #HealthcareInnovation #Networking #AdTherapies
-
-
And that’s a wrap for #IKS25! Our CEO Rapha?l G. Ognar, MSc MBA presented the latest updates on our development in the last session of the event, emphasizing how our unique off-the-shelf cel therapy could bring new options to more cancer patients. Thanks again to Hanson Wade Group for putting together a great event with many interactions options with our peers. Thanks to Selin Ibrahimov for leading and coordinating this event perfectly and thanks to all our peers for sharing, exchanging and challenging our ideas to build the cell therapies of the future. See you next time!
-
-
Live from #IKS25, our CSO/CDO Henri Bayle mapping out the key elements of our PD/CMC path forward and how we tackle challenges and she early with regulators to align and obtain buy in on how we will develop our technology with improved and efficient manufacturing process. Great discussions with a group of seasoned experts in the field that bring so many insights on how we can improve our manufacturing to bring better and safer products to patients. Thanks again to Mark Frohlich chairing the session and Yana Wang , Ignacio Nú?ez , John Yu and Chris Horan for their great insights.
-
-
Great start yesterday at the 10th Annual Innate Killer Summit #IKS25 with a plenary panel discussion. Our CEO Rapha?l G. Ognar, MSc MBA was surrounded by distinguished leaders from our field to set the tone of the day by exchanging on advances, opportunities and challenges we are seeing in NK cells therapeutics. Thank you to the session chair Kanya Rajangam (not in pic) and to all panelists, Adil Doganay Duru , Preet Chaudhary (not in pic), Mark Lowdell and Fred Aslan for their very interesting insights. Today our CEO will present the latest on our developments (1:30pm PST) and our CSO/CDO Henri Bayle is participating in another plenary panel to discuss manufacturing challenges and progresses (8:30am PST). #NKCells #allogeneic #offtheshelf #cancerresearch
-
-
Immediately on the heels of CAR-TCR Summit Europe, our leadership team is speaking at the 10th Annual Innate Killer Summit in San Diego, #IKS25, starting today for the next 3 days. Our CEO, Rapha?l G. Ognar, MSc MBA, will be participating in and industry fireside chat on Tuesday March 4th (8:30am PST), to discuss on challenges and advances in the field of NK cells with several distinguished leaders in the field. He is also presenting the latest updates on our developments on Wednesday March 5th (1:30pm PST) and will emphasize the set of opportunities we have to bring off-the-shelf cell therapy to more cancer patients, across hematologic and solid tumors. Our CSO/CDO, Henri Bayle, will also be involved by contributing to a panel discussion on Wednesday March 5th (8:30am PST), focused on process and manufacturing advances and improvements in the NK cell field. Another great event to discuss and exchange with top level specialists and experts in the field of Innate Immunity and NK cells. take this opportunity to reach out to our leaders and engage with them! #IKS25 #celltherapy #innate #offtheshelf #NKcells #cancerresearch #cancerpatients #allogeneic
-
-
Tomorrow the 10th Annual Innate Killer Summit, #IKS25, will launch and celebrate a decade of cell therapy & innate immunity innovation. NKILT Therapeutics, Inc. is very pleased to be part of the biotechs actively involved in the program, with both our CEO Rapha?l G. Ognar, MSc MBA and our CSO/CDO Henri Bayle presenting and contributing to this very exciting agenda. If you are involved in the field of Innate Immunity, cell therapy and NK cells, we really hope to meet you this week in San Diego to continue to push boundaries and bring more treatment options to patients in need.
-
-
A great event again as part of the CAR-TCR Summit Series, with this Europe version of it. Our company was showcased several times with our CEO Rapha?l G. Ognar, MSc MBA being involved in multiple roles throughout the conference, as Co-Chair of the C-Level Think Tank (with Gwendolyn Binder PhD), panelist talking about armoring technologies and in closing speaker to present the latest developments of our unique allogeneic CIR?NK cells technology. See you all at the next one in the US and/or in Europe!
That’s a wrap on the 8th CAR-TCR Summit Europe! The last 3 days have seen many connections forged between industry leaders and innovators, collectively pushing the boundaries of cell therapy. The discussions on advancing next-generation cell therapies were not only insightful but also showcased the remarkable potential these treatments hold for patients. A huge thank you to our speakers, partners, and attendees for your participation and insightful contributions. A special thanks to Tiffany Chen, David Fontana, Gwendolyn Binder PhD, Rapha?l G. Ognar, MSc MBA, Marc Davies, Rhine Shen, Robert Margolin, Felix Lorenz, Emilio Cosimo, Ph.D., Frederik De Vos, Peggy Sotiropoulou for their support in chairing the meeting and helping to facilitate meaningful conversations. Let’s continue to collaborate and drive forward the innovations that will improve patient outcomes. We hope to see you to celebrate a decade of engineering a disease-free world at the 10th CAR-TCR Summit Boston in September!
-
-
-
-
-
+1
-